The rotenone-induced Parkinsonism model uses chronic rotenone administration to reproduce the mitochondrial dysfunction central to Parkinson's disease pathogenesis. This toxin-based model produces selective dopaminergic degeneration and α-synuclein pathology.
Rotenone is a potent, selective inhibitor of mitochondrial complex I (NADH:ubiquinone oxidoreductase):
- Electron transport blockade: Prevents electron flow from NADH to ubiquinone
- ATP depletion: Impairs oxidative phosphorylation
- ROS generation: Increases reactive oxygen species at complex I
- Synaptic failure: Energy-dependent processes fail first
- Mitochondrial permeability transition: Pore opening, cytochrome c release
- Apoptosis activation: Caspase-dependent cell death
- α-Synuclein aggregation: Post-translational modification changes
- Neuroinflammation: Microglial activation secondary to neuronal stress
| Method |
Dose |
Duration |
Species |
| Subcutaneous pump |
2-3 mg/kg/day |
4-6 weeks |
Rat |
| Intragastric |
2-3 mg/kg/day |
4-8 weeks |
Rat |
| Intraperitoneal |
2-3 mg/kg/day |
4-6 weeks |
Mouse |
| Intravenous |
1-2 mg/kg/day |
2-4 weeks |
Rat |
- Solubility: Rotenone requires DMSO or Cremophor EL vehicle
- BBB penetration: Rotenone crosses the blood-brain barrier
- Systemic effects: Weight loss, gastrointestinal effects
- Animal welfare: Requires careful monitoring
- Dopaminergic neuron loss: 50-80% in substantia nigra pars compacta
- Striatal denervation: Loss of tyrosine hydroxylase-positive terminals
- VTA sparing: Relative preservation of ventral tegmental area neurons
- Neuronal vulnerability: Specific to dopaminergic neurons
- Phosphorylation: Increased pSer129 α-synuclein
- Aggregation: Cytoplasmic inclusion formation
- Lewy body-like structures: Characteristic round inclusions
- Progression: Pathology spreads with continued treatment
- Motor deficits: Reduced rotarod performance, cylinder test impairment
- Gait abnormalities: Reduced stride length, increased stance time
- Activity reduction: Decreased open field exploration
- Non-motor signs: Gastrointestinal dysfunction, olfactory deficits
- Complex I enhancers: CoQ10, methylene blue
- Antioxidants: N-acetylcysteine, vitamin D
- Anti-α-synuclein: Immunotherapies, aggregation inhibitors
- Anti-inflammatory: NLRP3 inhibitors, microglial modulators
- Mitochondrial cascade: Role of complex I deficiency in PD
- Cellular vulnerability: Why dopaminergic neurons are selectively affected
- α-Synuclein interaction: Mitochondrial dysfunction triggers aggregation
¶ Advantages and Limitations
- Mechanistic relevance: Targets complex I, a key pathway in PD
- α-Synuclein pathology: Produces inclusion formation
- Selective degeneration: Affects dopaminergic neurons
- Reproducible: Standardized protocols available
- Non-specific toxicity: Affects multiple cell types
- Systemic illness: Weight loss, GI effects confound interpretation
- Variable response: Animal-to-animal variability
- Acute model: Doesn't fully model chronic progression
- Betarbet et al., 2000 - Chronic rotenone model of PD
- Cannon et al., 2009 - Neuropathology in rotenone model
- Sherer et al., 2003 - Rotenone model mechanisms
- Johnson et al., 2019 - Rotenone model reproducibility